BCLXL and BCLXS as Resistance Markers for BCL2 Inhibitors in Melanoma

Felipe Dantas, The University of Texas at Austin
Evelyn de Groot, The University of Texas MD Anderson Cancer Center
Cesar Augusto Ruiz Elizondo, The University of Texas MD Anderson Cancer Center
Renato Guerrieri, The University of Texas MD Anderson Cancer Center
Michael A. Davies MD, PhD, The University of Texas MD Anderson Cancer Center
Vashisht YN Gopal, The University of Texas MD Anderson Cancer Center

Description